Nan Fung Ltd 13F annual report
Nan Fung Ltd is an investment fund managing more than $93.7 billion ran by Tang Nelson. There are currently 44 companies in Nelson’s portfolio. The largest investments include Illumina Inc and Harmony Biosciences Hldgs In, together worth $23.6 billion.
$93.7 billion Assets Under Management (AUM)
As of 6th August 2024, Nan Fung Ltd’s top holding is 119,196 shares of Illumina Inc currently worth over $12.4 billion and making up 13.3% of the portfolio value.
Relative to the number of outstanding shares of Illumina Inc, Nan Fung Ltd owns more than approximately 0.1% of the company.
In addition, the fund holds 368,665 shares of Harmony Biosciences Hldgs In worth $11.1 billion.
The third-largest holding is Merus N.V worth $7.1 billion and the next is Geron worth $5.82 billion, with 1,373,550 shares owned.
Currently, Nan Fung Ltd's portfolio is worth at least $93.7 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Nan Fung Ltd
The Nan Fung Ltd office and employees reside in Kai Tak, Hong Kong. According to the last 13-F report filed with the SEC, Tang Nelson serves as the Director at Nan Fung Ltd.
Recent trades
In the most recent 13F filing, Nan Fung Ltd revealed that it had opened a new position in
Geron and bought 1,373,550 shares worth $5.82 billion.
This means they effectively own approximately 0.1% of the company.
Geron makes up
9.6%
of the fund's Health Care sector allocation and has decreased its share price by approximately 0.1% in the past year.
The investment fund also strengthened its position in Merus N.V by buying
26,288 additional shares.
This makes their stake in Merus N.V total 120,038 shares worth $7.1 billion.
Merus N.V dropped approximately 0.1% in the past year.
On the other hand, there are companies that Nan Fung Ltd is getting rid of from its portfolio.
Nan Fung Ltd closed its position in Karuna Therapeutics Inc on 13th August 2024.
It sold the previously owned 225,688 shares for $44.3 billion.
Tang Nelson also disclosed a decreased stake in Xenon Pharmaceuticals Inc by approximately 0.1%.
This leaves the value of the investment at $4.16 billion and 106,680 shares.
One of the smallest hedge funds
The two most similar investment funds to Nan Fung Ltd are Vestia Personal Wealth Advisors and Incentive As. They manage $93.7 billion and $93.8 billion respectively.
Tang Nelson investment strategy
Nan Fung Ltd’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 65.0% of
the total portfolio value.
The fund focuses on investments in the United States as
47.7% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
9% of the total holdings value.
On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $4.69 billion.
The complete list of Nan Fung Ltd trades based on 13F SEC filings
These positions were updated on August 13th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
Security | Shares Owned | Value | Allocation |
---|---|---|---|
Karuna Therapeutics Inc |
Closed
225,688
|
$44,347,692,000 | |
Illumina Inc |
No change
119,196
|
$12,441,678,000 | 13.27% |
Harmony Biosciences Hldgs In |
No change
368,665
|
$11,122,623,000 | 11.87% |
Merus N.V |
28.04%
120,038
|
$7,102,648,000 | 7.58% |
Seagen Inc |
Closed
47,096
|
$6,052,307,000 | |
Geron Corp. |
Opened
1,373,550
|
$5,823,852,000 | 6.21% |
Oculis Holding Ag |
Opened
436,378
|
$5,214,717,000 | 5.56% |
Incyte Corp. |
115.24%
74,022
|
$4,487,214,000 | 4.79% |
Exscientia Plc |
0.80%
859,892
|
$4,385,449,000 | 4.68% |
Somalogic Inc |
Closed
1,696,558
|
$4,258,361,000 | |
Xenon Pharmaceuticals Inc |
6.73%
106,680
|
$4,159,453,000 | 4.44% |
Longboard Pharmaceuticals In |
Opened
144,570
|
$3,907,727,000 | 4.17% |
Mirum Pharmaceuticals Inc |
Opened
106,100
|
$3,627,559,000 | 3.87% |
Standard BioTools Inc |
Opened
1,883,179
|
$3,333,227,000 | 3.56% |
BeiGene Ltd |
91.50%
23,022
|
$3,284,549,000 | 3.50% |
Chinook Therapeutics, Inc. |
Closed
113,950
|
$2,985,490,000 | |
KalVista Pharmaceuticals Inc |
178.55%
219,277
|
$2,583,083,000 | 2.76% |
IVERIC bio Inc |
Closed
111,984
|
$2,397,577,000 | |
Rhythm Pharmaceuticals Inc. |
51.05%
49,120
|
$2,016,867,000 | 2.15% |
Tourmaline Bio Inc |
Opened
146,800
|
$1,887,848,000 | 2.01% |
Rani Therapeutics Hldgs Inc |
No change
493,584
|
$1,875,619,000 | 2.00% |
Ascendis Pharma A/S |
226.30%
13,600
|
$1,854,768,000 | 1.98% |
Replimune Group Inc |
8.24%
204,939
|
$1,844,451,000 | 1.97% |
Eargo, Inc. |
Closed
2,958,099
|
$1,700,907,000 | |
Acadia Pharmaceuticals Inc |
243.46%
102,984
|
$1,673,490,000 | 1.79% |
Madrigal Pharmaceuticals Inc |
380.71%
5,682
|
$1,591,869,000 | 1.70% |
Exelixis Inc |
No change
64,200
|
$1,442,574,000 | 1.54% |
Zai Lab Ltd |
Opened
55,000
|
$953,150,000 | 1.02% |
Galera Therapeutics Inc |
Closed
613,223
|
$913,702,000 | |
Biomarin Pharmaceutical Inc. |
76.86%
10,815
|
$890,399,000 | 0.95% |
Bolt Biotherapeutics Inc |
No change
1,166,952
|
$875,214,000 | 0.93% |
Entrada Therapeutics Inc |
33.30%
49,082
|
$699,419,000 | 0.75% |
Dbv Technologies S A |
Closed
370,950
|
$567,554,000 | |
Travere Therapeutics Inc |
Closed
25,606
|
$538,494,000 | |
Athira Pharma, Inc. |
Opened
180,000
|
$477,000,000 | 0.51% |
Affimed N.V. |
Closed
372,472
|
$461,865,000 | |
Argenx Se |
Closed
1,110
|
$420,501,000 | |
Pacific Biosciences Calif In |
100.86%
274,488
|
$376,049,000 | 0.40% |
Cabaletta Bio Inc |
Opened
47,150
|
$352,682,000 | 0.38% |
Bicycle Therapeutics plc |
Opened
17,300
|
$350,152,000 | 0.37% |
Roivant Sciences Ltd |
Opened
32,470
|
$343,208,000 | 0.37% |
Kymera Therapeutics, Inc. |
Opened
10,875
|
$324,619,000 | 0.35% |
GitLab Inc. |
Closed
6,910
|
$313,990,000 | |
Grail Inc |
Opened
19,866
|
$305,340,000 | 0.33% |
Revolution Medicines Inc |
Opened
7,300
|
$283,313,000 | 0.30% |
SpringWorks Therapeutics, Inc. |
Opened
7,450
|
$280,642,000 | 0.30% |
ALX Oncology Holdings Inc. |
No change
41,950
|
$252,959,000 | 0.27% |
Immunocore Hldgs Plc |
Opened
6,750
|
$228,758,000 | 0.24% |
Affimed N.V. |
Opened
37,247
|
$202,996,000 | 0.22% |
Immatics N.v |
Opened
15,700
|
$182,434,000 | 0.19% |
Biomea Fusion Inc |
33.33%
40,000
|
$180,000,000 | 0.19% |
Satsuma Pharmaceuticals, Inc. |
Closed
177,900
|
$160,110,000 | |
AbCellera Biologics Inc. |
307.08%
50,971
|
$150,874,000 | 0.16% |
Dbv Technologies S A |
Opened
185,475
|
$148,565,000 | 0.16% |
Nurix Therapeutics, Inc. |
Closed
11,500
|
$126,270,000 | |
Aerovate Therapeutics Inc |
5.29%
47,936
|
$79,574,000 | 0.08% |
Kodiak Sciences Inc |
62.68%
31,922
|
$75,017,000 | 0.08% |
FibroGen Inc |
82.10%
62,106
|
$55,417,000 | 0.06% |
Synlogic Inc |
Closed
68,634
|
$52,162,000 | |
Cerus Corp. |
Closed
14,172
|
$51,728,000 | |
Invitae Corp |
Closed
11,337
|
$21,087,000 | |
No transactions found | |||
Showing first 500 out of 61 holdings |
Hedge funds similar to Nan Fung Ltd
- Templeton & Phillips Capital Management
- Jones Road Capital Management, L.P.
- Fsa Advisors
- Trustco Bank Corp N Y
- Spartan Planning & Wealth Management
- Incentive As
- Vestia Personal Wealth Advisors
- Circumference
- Strategic Investment Management
- Skyknight Capital, L.P.
- Yorktown Management & Research Co Inc
- Charles Carroll Partners
- Private Harbour Investment Management & Counsel
- Cypress Capital Management (wy)